FredericMWaldmanMD
Pathology • San Francisco, CAAnatomic Pathology, Clinical Pathology
Medical Director, Cancer Diagnostics Quest Diagnostics Nichols Institute
Dr. Waldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 Divisadero St
San Francisco, CA 94143Phone+1 415-353-7241Fax+1 415-476-4150
Education & Training
University of California (San Francisco)Residency, Pathology-Anatomic and Clinical, 1980 - 1984
New York University School of MedicineClass of 1980
Certifications & Licensure
CA State Medical License 1982 - 2015
Clinical Trials
- Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Start of enrollment: 2002 Feb 19
Publications & Presentations
PubMed
- 7 citationsPrognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.Gang Wang, Peter C. Black, Peter J. Goebell, Lingyun Ji, Carlos Cordon-Cardo
Urologic Oncology. 2021-02-06 - 76 citationsThe molecular basis of breast cancer pathological phenotypesYujing J. Heng, Susan C. Lester, Gary M. Tse, Rachel E. Factor, Kimberly H. Allison
The Journal of Pathology. 2017-02-01 - 1 citationsMutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor SamplesHeather R. Sanders, Kevin Qu, Hai-Rong Li, Lin Ma, Cindy Barlan
Molecular Diagnosis & Therapy. 2016-04-15
Press Mentions
With Fall 2017 Cycle, UCSF’s Resource Allocation Program (RAP) Celebrates 10 Years of FundingAugust 25th, 2017
Grant Support
- Immunohistochemistry And Molecular PathologyNational Cancer Institute2007–2011
- Predictive Markers In Metastatic Renal CancerNational Cancer Institute2008–2010
- Bladder Cancer Risk And Genomic AlterationsNational Cancer Institute2007–2010
- Renal Cancer Genomic Alterations And Environmental Risk(Rmi)National Cancer Institute2007
- Renal Cancer Genomic Alterations And Environmental RiskNational Cancer Institute2003–2006
- Renal Cancer Genomic Alterations-Environmental Risk(Rmi)National Cancer Institute2005
- Genomic Markers Of Colon Cancer ProgressionNational Cancer Institute2001–2005
- Genetic Markers Of Bladder Cancer ProgressionNational Cancer Institute2001–2005
- Core--Immunohistochemistry/Molecular Pathology FacilityNational Cancer Institute2002
- Molecular/Cellular Predictors Of Breast Cancer PrognosisNational Cancer Institute1999–2000
- Breast Cancer Molecular CytogeneticsNational Cancer Institute1996–2000
- Neoplastic Progression In Ulcerative ColitisNational Cancer Institute1997–1999
- Cytometric And Other Markers Of Bladder CancerNational Cancer Institute1994–1999
- Molecular/Cellular Predictors Of Breast Cancer PrognosisNational Cancer Institute1997–1998
- Breast Cancer Molecular CytogeneticsNational Cancer Institute1995–1998
- Cytometric And Other Markers Of Human Bladder CancerNational Cancer Institute1992–1993
- Fluorescent Nuclear Organization--In Situ HybridizationNational Cancer Institute1989–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
